Progesterone: Which Tests to Order Alongside It

What Progesterone Actually Tells You (and What It Cannot)

Progesterone is a steroid hormone produced primarily by the corpus luteum after ovulation and by the placenta during pregnancy. A single mid-luteal value above 3 ng/mL confirms that ovulation occurred in that cycle, per the American Society for Reproductive Medicine (ASRM) Practice Committee opinion [1]. That is the limit of what the number alone can do.

It cannot tell you whether estrogen dominance is present. It cannot identify a pituitary lesion suppressing your cycle. It will not flag the subclinical hypothyroidism that quietly shortens your luteal phase. A progesterone level of 8 ng/mL on day 21 may look "normal" in isolation, yet paired with an estradiol of 450 pg/mL, the ratio points toward relative progesterone insufficiency. The Endocrine Society's 2015 clinical practice guideline on female infertility evaluation explicitly recommends concurrent hormone assessment rather than single-analyte testing [2]. Ordering progesterone without its companion labs is like reading one chapter of a textbook and calling it a diagnosis.

Estradiol: The Non-Negotiable Partner

Every progesterone draw should include a serum estradiol (E2). These two hormones exist in dynamic opposition across the menstrual cycle, and clinicians evaluate their ratio to assess endometrial receptivity and luteal adequacy.

During the mid-luteal phase, a healthy cycle typically shows estradiol between 100 and 300 pg/mL alongside progesterone of 10 to 25 ng/mL. The 2023 AACE reproductive endocrinology consensus notes that an estradiol-to-progesterone ratio exceeding 50:1 (measured in pg/mL to ng/mL) may indicate estrogen dominance, even when each individual value falls within reference range [3]. This ratio matters in HRT monitoring as well: women on cyclic progesterone supplementation need both values checked to confirm the progestogen is adequately opposing estrogen stimulation of the endometrium.

A practical framework for interpreting the pair: if estradiol is high and progesterone is low, suspect anovulation or luteal phase defect. If both are low, the problem likely sits upstream at the hypothalamus or pituitary. If both are high, consider pregnancy, ovarian hyperstimulation, or lab timing error.

LH and FSH: Reading the Pituitary Signal

Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) are the pituitary hormones that drive progesterone production. The mid-cycle LH surge triggers ovulation; without it, no corpus luteum forms and progesterone stays below 1 ng/mL. Ordering LH and FSH alongside progesterone separates ovarian failure from hypothalamic-pituitary dysfunction.

An FSH level above 25 mIU/mL with low progesterone and low estradiol points toward diminished ovarian reserve or premature ovarian insufficiency (POI). The ASRM defines POI as FSH above 25 mIU/mL on two draws at least 4 weeks apart in women under 40 [4]. A reversed LH-to-FSH ratio (LH exceeding FSH by more than 2:1) with low-normal progesterone is a classic finding in polycystic ovary syndrome. In the Rotterdam criteria validation cohort (N=1,297), 68% of women meeting PCOS criteria had an LH:FSH ratio above 2 [5].

Draw LH and FSH on cycle day 3 for baseline assessment or on the same day as your mid-luteal progesterone if the clinical question is whether the LH surge fired appropriately. Both approaches yield actionable data, but they answer different questions.

Thyroid Panel: TSH and Free T4

Subclinical hypothyroidism affects roughly 4.3% of the U.S. population aged 12 and older, according to NHANES data published by the CDC [6]. In reproductive-age women, even mild TSH elevation (2.5 to 4.5 mIU/L) associates with shorter luteal phases and lower mid-luteal progesterone. A 2017 systematic review in the Journal of Clinical Endocrinology & Metabolism (15 studies, N=14,753) found that women with subclinical hypothyroidism had a 1.46-fold increased risk of anovulation compared to euthyroid controls [7].

The Endocrine Society's 2012 guideline on thyroid disease in pregnancy recommends a TSH target below 2.5 mIU/L for women attempting conception [8]. Dr. Alex Stagnaro-Green, lead author of that guideline, stated: "Thyroid autoimmunity and subclinical hypothyroidism are independent risk factors for miscarriage, and screening should accompany any fertility-focused hormone panel" [8].

Order TSH and free T4 together. TSH alone misses central hypothyroidism, which presents with a normal or low TSH but low free T4. This pattern is uncommon but clinically significant, particularly if the progesterone draw already suggests pituitary-level dysfunction.

Fasting Insulin and Glucose

Insulin resistance is the metabolic engine behind many anovulatory cycles. In PCOS, which accounts for 80% of anovulatory infertility per the WHO classification [9], hyperinsulinemia directly suppresses sex hormone-binding globulin (SHBG) and increases ovarian androgen production. The net effect: disrupted folliculogenesis and inadequate progesterone output.

A fasting insulin above 12 µU/mL with a fasting glucose below 100 mg/dL suggests compensated insulin resistance. The HOMA-IR calculation (fasting insulin × fasting glucose ÷ 405) provides a standardized metric; values above 2.5 indicate resistance. In the Diabetes Prevention Program (DPP) trial (N=3,234), participants with HOMA-IR above 3.0 had a 58% higher progression rate to type 2 diabetes over 2.8 years [10].

For the progesterone panel specifically, fasting insulin tells you whether metabolic correction (metformin, inositol, dietary intervention) is likely to restore ovulatory cycles without hormonal supplementation. Adding hemoglobin A1c extends the metabolic snapshot to a 90-day average. The ADA Standards of Care 2024 recommend HbA1c screening for all adults with BMI above 25 kg/m² and one additional risk factor [11].

DHEA-S: Sorting Out the Androgen Source

Dehydroepiandrosterone sulfate (DHEA-S) is produced almost exclusively by the adrenal glands, making it a clean marker for adrenal androgen excess. When a woman presents with low progesterone, irregular cycles, and elevated total testosterone, DHEA-S separates the adrenal contribution from ovarian hyperandrogenism.

An elevated DHEA-S (above 350 µg/dL in reproductive-age women, though lab-specific ranges vary) alongside normal ovarian androgens points toward non-classic congenital adrenal hyperplasia (NCAH) or adrenal PCOS phenotype. The Endocrine Society's 2018 PCOS guideline recommends measuring DHEA-S and 17-hydroxyprogesterone in any woman with hyperandrogenism to exclude NCAH, which has a prevalence of 1 to 2% in hyperandrogenic women [12]. A morning 17-hydroxyprogesterone below 200 ng/dL effectively rules out the condition.

This is a single additional tube at the same draw. The cost is minimal and the diagnostic yield is high, especially in women under 30 with acne, hirsutism, and cycle irregularity that predates oral contraceptive use.

Prolactin: The Overlooked Suppressor

Hyperprolactinemia suppresses gonadotropin-releasing hormone (GnRH) pulsatility, which in turn reduces LH pulse frequency and amplitude. The downstream result is anovulation and low progesterone. Mild elevations (25 to 50 ng/mL) may produce subtle cycle changes rather than the classic amenorrhea seen at higher levels.

The Endocrine Society's 2011 clinical practice guideline on hyperprolactinemia, authored by Dr. Shlomo Melmed and colleagues, states: "All women with unexplained oligo-amenorrhea should have serum prolactin measured, as hyperprolactinemia is present in up to 30% of women with secondary amenorrhea" [13]. That 30% figure makes prolactin one of the highest-yield additions to a progesterone panel.

Draw prolactin fasting, in the morning, and at least one hour after waking. Stress, nipple stimulation, and recent meals all transiently raise prolactin, producing false positives. A confirmed elevation above 25 ng/mL warrants pituitary MRI to rule out prolactinoma.

Timing the Draw: Why Day 21 Exists

Progesterone rises after ovulation and peaks roughly 7 days later. In a textbook 28-day cycle, that peak falls on day 21. But cycles vary. A woman with a 35-day cycle ovulates around day 21, so her progesterone peak arrives near day 28.

The correct instruction is not "come in on day 21" but "come in 7 days after you ovulate." Ovulation can be confirmed with urinary LH kits (the surge precedes ovulation by 24 to 36 hours), basal body temperature shift, or ultrasound follicle tracking. The ASRM Practice Committee recommends that mid-luteal progesterone be drawn 7 days post-ovulation for accurate interpretation, noting that mistimed draws are the most common source of falsely low results [1].

All paired tests (estradiol, LH, FSH, prolactin) can be drawn at the same time as the progesterone. Thyroid function and fasting insulin are cycle-independent, so they can be added to any fasting morning draw without scheduling constraints.

When to Add a Full Metabolic Panel

Not every patient needs every test listed above. A 25-year-old with regular 28-day cycles checking progesterone to confirm ovulation before attempting conception may only need estradiol and TSH added. A 34-year-old with 45-day cycles, BMI of 32, and acne needs the full panel: estradiol, LH, FSH, TSH, free T4, fasting insulin, fasting glucose, HbA1c, DHEA-S, total testosterone, prolactin, and 17-hydroxyprogesterone.

Clinical context determines panel depth. The AACE 2023 guidelines recommend a "tiered approach" where the initial screen includes progesterone, estradiol, TSH, and prolactin, with second-tier testing (androgens, insulin, adrenal markers) triggered by abnormal findings or high clinical suspicion for PCOS, NCAH, or metabolic syndrome [3].

Cost is a real consideration. A comprehensive panel through a direct-to-consumer lab runs $200 to $400 out of pocket. Through insurance with appropriate ICD-10 coding (N91.1 for oligomenorrhea, N97.0 for anovulatory infertility, E28.2 for PCOS), most payers cover the full set. Ordering everything on one draw eliminates repeat visits, repeat copays, and the diagnostic delay that comes with sequential single-test ordering.

Interpreting Results as a Panel, Not Individual Numbers

A common clinical error is evaluating each result against its reference range in isolation. Reference ranges describe population distributions, not clinical thresholds. A progesterone of 5 ng/mL is "within range" for the luteal phase, but paired with an estradiol of 380 pg/mL and an LH:FSH ratio of 3:1, it tells a story of PCOS with inadequate luteal support.

The panel approach also catches compensated dysfunction. A woman with TSH of 3.8 mIU/L (technically "normal" by most lab ranges) and progesterone of 6 ng/mL on cycle day 21 might benefit from low-dose levothyroxine to optimize thyroid function before starting progesterone supplementation. The ASRM and the Endocrine Society both endorse treating subclinical hypothyroidism in women planning pregnancy when TSH exceeds 2.5 mIU/L [8].

Pattern recognition across the panel is the diagnostic skill that single-analyte ordering cannot provide. Order the panel. Read the panel. Treat the pattern.